Technology evaluation: denosumab, Amgen

Bo Abrahamsen; Andy Y T Teng

Technology evaluation: denosumab, Amgen

Bo Abrahamsen, Andy Y T Teng

20 Citations (Scopus)

Abstract

Amgen, as part of its program targeting the RANK/RANKL/ osteoprotegerin pathway, is developing denosumab, a fully human monoclonal antibody, delivered subcutaneously, targeting the receptor activator of nuclear factor-kappaB ligand, for the potential treatment of diseases associated with bone loss, such as osteoporosis and bone metastases. The antibody is currently undergoing phase III clinical trials.

Original language	English
Journal	Current Opinion in Molecular Therapeutics
Volume	7
Issue number	6
Pages (from-to)	604-10
Number of pages	7
ISSN	1464-8431
Publication status	Published - Dec 2005
Externally published	Yes

Keywords

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Clinical Trials as Topic
Drug Evaluation, Preclinical
Drug Industry
Humans
Patents as Topic
RANK Ligand

Cite this

@article{08961fa40f6f4b19a868fb4ce1fff170,

title = "Technology evaluation: denosumab, Amgen",

abstract = "Amgen, as part of its program targeting the RANK/RANKL/ osteoprotegerin pathway, is developing denosumab, a fully human monoclonal antibody, delivered subcutaneously, targeting the receptor activator of nuclear factor-kappaB ligand, for the potential treatment of diseases associated with bone loss, such as osteoporosis and bone metastases. The antibody is currently undergoing phase III clinical trials.",

keywords = "Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Clinical Trials as Topic, Drug Evaluation, Preclinical, Drug Industry, Humans, Patents as Topic, RANK Ligand",

author = "Bo Abrahamsen and Teng, \{Andy Y T\}",

year = "2005",

month = dec,

language = "English",

volume = "7",

pages = "604--10",

journal = "Current Opinion in Molecular Therapeutics",

issn = "1464-8431",

publisher = "Thomson Scientific Ltd.",

number = "6",

}

TY - JOUR

T1 - Technology evaluation

T2 - denosumab, Amgen

AU - Abrahamsen, Bo

AU - Teng, Andy Y T

PY - 2005/12

Y1 - 2005/12

N2 - Amgen, as part of its program targeting the RANK/RANKL/ osteoprotegerin pathway, is developing denosumab, a fully human monoclonal antibody, delivered subcutaneously, targeting the receptor activator of nuclear factor-kappaB ligand, for the potential treatment of diseases associated with bone loss, such as osteoporosis and bone metastases. The antibody is currently undergoing phase III clinical trials.

AB - Amgen, as part of its program targeting the RANK/RANKL/ osteoprotegerin pathway, is developing denosumab, a fully human monoclonal antibody, delivered subcutaneously, targeting the receptor activator of nuclear factor-kappaB ligand, for the potential treatment of diseases associated with bone loss, such as osteoporosis and bone metastases. The antibody is currently undergoing phase III clinical trials.

KW - Antibodies, Monoclonal

KW - Antibodies, Monoclonal, Humanized

KW - Clinical Trials as Topic

KW - Drug Evaluation, Preclinical

KW - Drug Industry

KW - Humans

KW - Patents as Topic

KW - RANK Ligand

UR - https://www.scopus.com/pages/publications/28844502782

M3 - Journal article

C2 - 16370384

SN - 1464-8431

VL - 7

SP - 604

EP - 610

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

IS - 6

ER -

Technology evaluation: denosumab, Amgen

Abstract

Keywords

Other files and links

Fingerprint

Cite this